Syntax Bio
$20.0M
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
Syntax Bio is currently valued at N/A as of September 18, 2024. The company has raised a total of $33.5M in funding.
Investment Perspective
Syntax Bio's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is Syntax Bio Worth in 2025?
As of 2025, Syntax Bio is valued at N/A, based on the company's Later Stage VC funding round in September 18, 2024. This valuation positions Syntax Bio as one of the leading private companies in the sector.
Syntax Bio Valuation History
Syntax Bio's funding history demonstrates steady growth and investor confidence.
How Syntax Bio Valuation is Determined
Private company valuations like Syntax Bio's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
Syntax Bio Valuation FAQs
Is Syntax Bio profitable?
Syntax Bio has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does Syntax Bio's valuation compare to competitors?
Syntax Bio is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will Syntax Bio IPO?
Syntax Bio has not announced plans for an initial public offering. Until an IPO, investors can access Syntax Bio shares through secondary market platforms.